Columbus, OH
Founders and CEO
Richard Shea
Life Sciences

Company Profile

Basking Biosciences is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031. Basking’s paired therapy has the potential to significantly expand the population of patients that receive acute thrombolytic therapy and aligns perfectly with the urgent need in medicine for precision-based therapeutics in cardiovascular disease.

Blogs About Basking Biosciences

Video: Basking Biosciences Develops Novel Treatment for Stroke
Basking Bioscience Can Treat the 600,000 Stroke Victims Every Year
Welcoming Two New Startups to Rev1’s Investor Startup Studio
Investor Startup Studio

Basking Biosciences in the News

Ohio State-Duke spinoff Basking Biosciences raises $55M to test stroke treatment
Basking Biosciences closes US$55 million financing to further reversible stroke thrombolytic
Basking Biosciences Closes $5.4M Seed Financing